| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/28/2013 | US20130053320 Treatment of anemia by adnp and adnf polypeptides |
| 02/28/2013 | US20130053319 Chemokine derived peptides and uses for chronic wound and angiogenesis inhibition treatments |
| 02/28/2013 | US20130053318 Modulating aquaporins with relaxin |
| 02/28/2013 | US20130053317 Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| 02/28/2013 | US20130053316 Methods for Treating Disorders of the Gastrointestinal Tract Using a GLP-1 Agonist |
| 02/28/2013 | US20130053315 Novel glp-1 derivatives |
| 02/28/2013 | US20130053314 Mutant Epidermal Growth Factor Polypeptides with Improved Biological Activity and Methods of Their Making and Use |
| 02/28/2013 | US20130053313 New formulation for increasing bioavailability of neurturin |
| 02/28/2013 | US20130053312 Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes |
| 02/28/2013 | US20130053311 Glp-1 analogues and derivatives |
| 02/28/2013 | US20130053310 Novel glucagon analogues |
| 02/28/2013 | US20130053309 Substituted diketopiperazine analogs for use as drug delivery agents |
| 02/28/2013 | US20130053308 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| 02/28/2013 | US20130053307 Method for weight loss aided by administration of human chorionic gonadotropin |
| 02/28/2013 | US20130053306 Use of histones for the early diagnosis and/or preventive therapy of virally-infected living cells and a biochip for carrying out said diagnosis |
| 02/28/2013 | US20130053305 Peptide compounds that can be used as antibacterial agents |
| 02/28/2013 | US20130053304 Glucagon-like peptide-1 analogues and uses thereof |
| 02/28/2013 | US20130053303 Compounds for enzyme inhibition |
| 02/28/2013 | US20130053302 Treatment Of Sepsis Using Complement Inhibitors |
| 02/28/2013 | US20130053301 Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| 02/28/2013 | US20130052737 Method for selective electrofusion of at least two fusion partners having cell-like membranes |
| 02/28/2013 | US20130052677 PEG-Urate Oxidase Conjugates and Use Thereof |
| 02/28/2013 | US20130052667 Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| 02/28/2013 | US20130052280 Use of thebromine for lowering central blood pressure |
| 02/28/2013 | US20130052274 Nutritional compositions including exogenous vitamin k2 |
| 02/28/2013 | US20130052268 Compositions and methods for treatment of parkinson's disease |
| 02/28/2013 | US20130052258 Polypeptides and uses thereof |
| 02/28/2013 | US20130052250 Compounds and methods for biofilm disruption and prevention |
| 02/28/2013 | US20130052245 Cosmetic and dermatological formulations of mntf peptides |
| 02/28/2013 | US20130052240 Dermal micro-organs, methods and apparatuses for producing and using the same |
| 02/28/2013 | US20130052237 Methods of Manufacturing Viscous Liquid Pharmaceutical Formulations |
| 02/28/2013 | US20130052236 Composite polylactic acid/alginate surgical barrier |
| 02/28/2013 | US20130052232 Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
| 02/28/2013 | US20130052229 Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| 02/28/2013 | US20130052210 Use of ccl1 in therapy |
| 02/28/2013 | US20130052198 Anti-inflammatory factors |
| 02/28/2013 | US20130052184 Gelatinase inhibitors and prodrugs |
| 02/28/2013 | US20130052183 Methods for the treatment of morgellons disease |
| 02/28/2013 | US20130052182 Method of reducing biofilms |
| 02/28/2013 | US20130052181 Combined use of ribonuclease and artemisinin |
| 02/28/2013 | US20130052180 Method for producing lipase, transformed yarrowia lipolytica cell capable of producing said lipase and their uses |
| 02/28/2013 | US20130052179 Arginine deiminase mutant and preparation and application thereof |
| 02/28/2013 | US20130052178 Cholesterol ester for reducing cholesterol absorption |
| 02/28/2013 | US20130052177 MONOMERIC FORMS OF HUMAN AMINOACYL-t-RNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES |
| 02/28/2013 | US20130052176 Aptamer for ngf and use thereof |
| 02/28/2013 | US20130052175 Oil suspension-based molded food products |
| 02/28/2013 | US20130052172 Methods for diagnosing and treating cardiac defects |
| 02/28/2013 | US20130052168 Methods and compositions for tissue regeneration |
| 02/28/2013 | US20130052167 Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content |
| 02/28/2013 | US20130052162 Boosting immune defense by upregulating ccaat/enhancer binding protein epsilon |
| 02/28/2013 | US20130052161 Inhibitors of flaviviridae viruses |
| 02/28/2013 | US20130052160 Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| 02/28/2013 | US20130052159 Methods for treatment of microbial disorders |
| 02/28/2013 | US20130052158 Use of autologous effector cells for treatment of multiple myeloma |
| 02/28/2013 | US20130052157 Use of il-17e for cancer treatment |
| 02/28/2013 | US20130052155 Compositions and Methods for Treating a Disorder or Defect in Soft Tissue |
| 02/28/2013 | US20130052154 Compositions and Methods for the Treatment of Lung Inflammation |
| 02/28/2013 | US20130052135 Molecules With Extended Half-Lives, Compositions And Uses Thereof |
| 02/28/2013 | US20130052131 Nanoparticles, methods of making nanoparticles, and methods of use |
| 02/28/2013 | DE102010039018B4 Anti-La Antikörper und ihre Anwendung zum Immunotargeting Anti-La antibodies and their application to Immunotargeting |
| 02/28/2013 | CA2846629A1 Methods and compositions comprising a c-terminalbax peptide |
| 02/28/2013 | CA2846494A1 Compounds for use in boosting coagulation |
| 02/28/2013 | CA2844811A1 Methods for weight loss and ketogenic compositions |
| 02/28/2013 | CA2844386A1 Crystal forms of a hcv protease inhibitor |
| 02/27/2013 | EP2562181A1 Potent ligands of the ghrelin receptor |
| 02/27/2013 | EP2561889A2 Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| 02/27/2013 | EP2561888A1 Protein comprising NC-1 for treating angiogenesis-related diseases |
| 02/27/2013 | EP2561887A2 Cancer therapy sensitizer |
| 02/27/2013 | EP2561886A1 Peptide adjuvant for improved peripheral analgesia |
| 02/27/2013 | EP2561885A2 Use of hades as tumor suppressor target |
| 02/27/2013 | EP2561884A1 Chimeric VEGF peptides |
| 02/27/2013 | EP2561879A1 Macrophage activating factor for use in the treatment of chronic fatigue syndrome (CFS) and CFS-related diseases and disorders |
| 02/27/2013 | EP2561873A1 Structural mimetics of proline-rich peptides and use of same |
| 02/27/2013 | EP2561089A2 Method of determining the metastatic potential of a tumor |
| 02/27/2013 | EP2561072A2 Nanozymes, methods of making nanozymes, and methods of using nanozymes |
| 02/27/2013 | EP2561069A2 Lysosomal storage disease enzyme |
| 02/27/2013 | EP2561068A1 Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity |
| 02/27/2013 | EP2560991A1 Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof |
| 02/27/2013 | EP2560989A1 Cancer-related glycopeptide epitopes, antibodies and methods of use |
| 02/27/2013 | EP2560686A2 Selective modification of proteins |
| 02/27/2013 | EP2560679A1 Eczema treatment |
| 02/27/2013 | EP2560678A1 Pharmaceutical compositions |
| 02/27/2013 | EP2560677A1 Cold treatment |
| 02/27/2013 | EP2560675A1 Long-acting gastrin derivatives |
| 02/27/2013 | EP2560674A2 Nanoparticle targeting to ischemia for imaging and therapy |
| 02/27/2013 | EP2560673A1 Hb-egf composition and use thereof to treat a condition associated with enhanced urothelium permeability |
| 02/27/2013 | EP2560672A1 Rtef-1 variants and uses thereof |
| 02/27/2013 | EP2560671A2 High affinity leptins and leptin antagonists |
| 02/27/2013 | EP2560670A2 Uses of natriuretic peptide constructs |
| 02/27/2013 | EP2560669A1 Casein peptide for use in the treatment of uterine infections |
| 02/27/2013 | EP2560668A1 Methods of treating glucose metabolism disorders |
| 02/27/2013 | EP2560667A1 Method to detect endothelial cell massive calcium accumulation death |
| 02/27/2013 | EP2560660A1 Chemosensory receptor ligand-based therapies |
| 02/27/2013 | EP2560644A1 A pharmaceutical composition comprising antiplatelet agents and an erythropoiesis stimulating agent |
| 02/27/2013 | EP2560637A2 Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells |
| 02/27/2013 | EP2560629A2 Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
| 02/27/2013 | EP2560625A2 Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same |
| 02/27/2013 | CN102947444A Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases |
| 02/27/2013 | CN102947332A Novel octapeptide compounds and therapeutic use thereof |
| 02/27/2013 | CN102947326A Ccn3 peptides and analogs thereof for therapeutic use |